This company has been marked as potentially delisted and may not be actively trading. IMARA (IMRA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsInsider TradesTrendsBuy This Stock IMRA vs. MOR, GMTX, CALT, ZYME, SBTX, MBX, AVTE, NLTX, BIOA, and ELYMShould you be buying IMARA stock or one of its competitors? The main competitors of IMARA include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), and Eliem Therapeutics (ELYM). IMARA vs. Its Competitors MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks Silverback Therapeutics MBX Biosciences Aerovate Therapeutics Neoleukin Therapeutics BioAge Labs Eliem Therapeutics IMARA (NASDAQ:IMRA) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation. Do insiders & institutionals have more ownership in IMRA or MOR? 49.3% of IMARA shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 37.3% of IMARA shares are owned by insiders. Comparatively, 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media prefer IMRA or MOR? In the previous week, MorphoSys' average media sentiment score of 0.00 beat IMARA's score of 0.00 indicating that MorphoSys is being referred to more favorably in the news media. Company Overall Sentiment IMARA Neutral MorphoSys Neutral Is IMRA or MOR more profitable? IMARA has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. IMARA's return on equity of 2.12% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets IMARAN/A 2.12% 2.00% MorphoSys -226.79%-694.31%-22.55% Which has higher valuation and earnings, IMRA or MOR? IMARA has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than IMARA, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIMARAN/AN/A$1.49M$0.05797.20MorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Which has more risk and volatility, IMRA or MOR? IMARA has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. SummaryIMARA beats MorphoSys on 8 of the 11 factors compared between the two stocks. Get IMARA News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRA vs. The Competition Export to ExcelMetricIMARAPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.05B$852.55M$5.74B$10.30BDividend YieldN/A4.84%5.86%4.62%P/E Ratio797.361.2276.8026.52Price / SalesN/A123.38448.8087.93Price / Cash75.2419.5637.2260.63Price / Book11.596.5814.066.31Net Income$1.49M-$4.18M$3.29B$271.37M IMARA Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRAIMARAN/A$39.86-0.4%N/AN/A$1.05BN/A797.3641MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730GMTXGemini TherapeuticsN/A$61.91+1.9%N/A+26.6%$2.68BN/A-61.9130High Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks2.5042 of 5 stars$15.23+0.3%$21.43+40.7%+29.0%$1.14B$122.87M-10.15460Positive NewsSBTXSilverback TherapeuticsN/A$10.70+6.3%N/A-27.3%$385.82MN/A-4.4283High Trading VolumeMBXMBX Biosciences2.8346 of 5 stars$11.42+4.8%$37.63+229.5%N/A$366.18MN/A-2.5236Positive NewsAVTEAerovate TherapeuticsN/A$7.48-3.7%N/A-89.3%$216.81MN/A-2.5020High Trading VolumeNLTXNeoleukin TherapeuticsN/A$19.45-2.5%N/A-56.7%$182.79MN/A-6.2590High Trading VolumeBIOABioAge Labs0.1375 of 5 stars$4.98-2.2%N/AN/A$182.48MN/A0.00N/AELYMEliem TherapeuticsN/A$2.47+3.3%N/A-74.7%$152.03MN/A-4.669 Related Companies and Tools Related Companies MorphoSys Alternatives Gemini Therapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives Zymeworks Alternatives Silverback Therapeutics Alternatives MBX Biosciences Alternatives Aerovate Therapeutics Alternatives Neoleukin Therapeutics Alternatives BioAge Labs Alternatives Eliem Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRA) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMARA Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMARA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
